Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DAYTRANA® safely and effectively. See full prescribing information for DAYTRANA. DAYTRANA® (methylphenidate transdermal system), CII Initial U.S. Approval: 2006
Medication labelWhy this: Advisory · dailymed-prescription
DAYTRANA (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Use The use of DAYTRANA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.8), Use in Specific Populations (8.4)] .
- generic_name
- methylphenidate
- product_names
- methylphenidate
- ndc
- 68968-5552, 68968-5553, 68968-5554, 68968-5555, 68968-5552-3, 68968-5553-3, 68968-5554-3, 68968-5555-3
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en